CLINICAL IMMUNOLOGY
Original inhibition method of excessive synthesis of pro-inflammatory cytokine of tumour necrosis factor α
 
More details
Hide details
 
Submission date: 2015-02-23
 
 
Final revision date: 2015-04-27
 
 
Acceptance date: 2015-05-14
 
 
Publication date: 2015-10-15
 
 
Cent Eur J Immunol 2015;40(3):345-348
 
KEYWORDS
ABSTRACT
Influence on pro- and anti-inflammatory cytokines of an ill person is an urgent aspect of treatment of many diseases. For inhibition of synthesis of a high level of pro-inflammatory cytokines, medications which are recombinant monoclonal antibodies, especially to tumour necrosis factor α (TNF-α), are used. However, these methods of treatment require further improvement by elaborating new approaches with a wider spectrum of influence on the immune system.
A completely new method of reduction in high activity of TNF-α with the method of intradermal autoleukocyte immunization is presented in the article. Investigation was performed in a group of patients with psoriasis (24) with a high level of TNF-α in the blood (over 30 pg/ml). Simultaneously such investigation was performed on patients with psoriasis (9) without TNF-α detected (0 pg/ml).
As a result of immunization, a significant reduction in TNF-α occurred in all patients with its high level, in 16 (66.7%) from 24 patients – to 0-5 pg/ml. The level of reduction and duration of the achieved effect was of an individual character and requires further investigation. However, the achieved results prove the expediency of administration of this immunization method for patients requiring reduction of TNF-α synthesis.
However, the content of TNF-α in blood serum could not be detected in most patients with a low level of cytokine (in 6 from 9) after immunization (as well as before immunization), but an increase in its level from 0 to 5-8 pg/ml was observed in 3 patients. On the basis of the conducted research, the authors suggest that the influence of immunization on cytokine synthesis depends on the condition of immune cells and correlation of pro- and anti-inflammatory cytokines in a patient’s skin.
REFERENCES (27)
1.
Murphy JE, Robert C, Kupper TS (2000): Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity J Invest Dermatol 2000; 114: 602-608.
 
2.
Boris LC, Steinke JW (2003): Cytokines and chemokines J Allergy Clin Immunol. 2003; 111 (2 Suppl): S460-S475.
 
3.
Gupta S, Gollapudi S (2005): Molecular mechanisms of TNF-αlpha-induced apoptosis in aging human T cell subsets. Int J Biochem Cell Biol 37: 1034-1042.
 
4.
Tousoulis D, Antoniades C, Vassiliadou C, et al. (2005): Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 7: 1126-1132.
 
5.
Gao B, Bataller R (2011): Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 5: 1572-1585.
 
6.
Miller AM, Horiguchi N, Jeong WI, et al. (2011): Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines. Alcohol Clin Exp Res 2011; 35: 787-793.
 
7.
Neuman MG (2003): Cytokines in alcoholic liver. Alcohol Res Health 2003; 27: 307-316.
 
8.
Drannik HN (2010): Clinical immunology and allergology. Kiev, 2010.
 
9.
Wellen KE, Gökhan S (2005): Hotamisligil. Inflammation, stress, and diabetes. J Clin Invest 115: 1111-1119.
 
10.
Mann DL (2002): Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91: 988-998.
 
11.
Tabet JY, Lopes ME, Champagne S, et al. (2002): Inflammation, cytokines and anti-inflammatory therapies in heart failure. Arch Mal Coeur Vaiss 95: 204-212.
 
12.
Sygydyn YA, Skurkovych BS, Lunina GV (1998): New approaches to biological immunomodulating therapy of rheumatoid arthritis: neutralization of basic cytokines, Therapeutic Archives 5: 32-37.
 
13.
Granstein RD (2001): New treatments for psoriasis. N Engl J Med 345: 284-287.
 
14.
Badokin VV (2005): Perspectives of administration of TNF inhibitors in psoriasis and psoriatric arthritis. Clinical pharmacological therapy, 14: 76-79.
 
15.
Brimhall AK, King LN, Licciardone JC, et al. (2008): Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 159: 274-285.
 
16.
Schellekens H (2002): Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24: 1720-1740.
 
17.
Anderson PJ (2005): Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34: 19-22.
 
18.
Lobo ED, Hansen RJ, Balthasar JP (2004): Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-2668.
 
19.
Herasun BA, Chopiak VV, Vorozhbyt OB (2006): Treatment of autoimmune disorders caused by chronic hepatitis B and C by means of autoleukocyte immunization. Mir Virusnykh Hepatitov Moscow 1: 13-18.
 
20.
Chopyak VV, Hospodarskyi IY, Herasun BA (2006): Clinical algorythm of providing medical aid to patients with polyclonic (mixed) cryoglobulinemic syndrome – D 89.1. – Methodological guide of Ministry of Health of Ukraine, Kyiv, 2006.
 
21.
Herasun BA, Andreychyn MA, Hrytsko RY, et al. (2012): Use of leukocytes in cell therapy. Gepatologia 2: 4-17.
 
22.
Herasun BA, Kopets RA (2012): Application of the method of autoleukocytes 264 vaccination as the method of treatment of oligo- and astenozoospermia. UA97461 (2012).
 
23.
Gerasun BA, Holubovska OA, Hrytsko RY, et al. (2014): Reduction of hyperproduction of thyroid autoantibodies in patients without disturbance of the thyroid function: new patents. Recent Pat Endocr Metab Immune Drug Discov 8:140-145.
 
24.
Gerasun B, Kopets R, Hrytsko R, Gerasun O (2013): Correction of fertility disorders in patients with cryoglobulinemia. Cent European J Urol 2013; 66: 316-319.
 
25.
Patent for useful model № 97493. Use of the method of autoleukocyte vaccination as the inhibition method of the synthesis of pro-inflammatory cytokine of TNF-αlpha in patients with psoriasis. Herasun BA; Ukraine, published 10.03.2015.
 
26.
Herasun BA, Hrytsko RY (2012): Original treatment method of frequently recurrent chronic herpetic infection caused by herpes simplex virus I and II types. Centr Eur J Immunol 37: 362-364.
 
27.
Golab J, Jakobisiak M, Lasek W, Stoklosa T. Immunologia. Wydawnictwo Naukowe PWN, Warszawa 2007; 1-511.
 
eISSN:1644-4124
ISSN:1426-3912
Journals System - logo
Scroll to top